MTOR and graft versus host disease: Given the shortcomings of PTCy as monotherapy for GvHD prophylaxis following MRD and MUD peripheral blood transplants, several groups reverted to combining PTCy with a CNI or mTORI with or without MMF, aiming to reduce the relatively high incidence of cGvHD characteristic of CNI and mTOR inhibitors-based combinations.